Medical systems provider, MAQUET Cardiovascular, has obtained CE Mark approval for its new Intergard Synergy antimicrobial vascular graft.
The Intergard Synergy graft releases broad spectrum antimicrobial agents, including silver acetate and triclosan, from its surface to help prevent infection following vascular reconstructive surgery.
The antimicrobial vascular graft showed antimicrobial efficacy against a broad spectrum of micro-organisms, including methicillin-resistant Staphylococcus aureus (MRSA), and was more effective than the first-generation Intergard silver graft, during the in vitro testing.
Krankenhaus Nordwest spokesperson, Max Zegelman, said the new Intergard Synergy uses two effective antimicrobial agents to fight against acquired infection in vascular surgery patients.
"This new infection protection holds the potential to enhance my ability to ensure that my vascular surgery patients remain infection free," Zegelman added.
"I have long been an advocate of antimicrobial coatings on surgical prosthesis, even though there is not yet evidence-based demonstration of their impact on overall infection rates."
MAQUET Cardiovascular president and CEO, Christian Keller, said: "The Intergard Synergy graft is another example of MAQUET Cardiovascular's commitment to providing customers with new and innovative solutions that improve patient care for years to come."